Medication info
Lidipome Sustained Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Lidipome Sustained Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
Oval sustained release tablet in white to nearly white color imprinted with L2M on one side
Packaging
28 tablets/box [7 tablets/PTP x 4], 30 tablets/bottle
Approval status
Active

MFDS item code 202400622 · Approved 2024.03.22 · Insurance code 645907530

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride, as extended-release, 2000 mg. This medicine should be taken with food once daily, preferably with the evening meal. For this medicine 5/1000 mg extended-release tablets, take 1 tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin therapy - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medicine serves to complement dietary and exercise regimens for patients with type 2 diabetes who are taking linagliptin and metformin together, aiding in blood glucose control. Specifically, it effectively manages blood glucose levels, assisting in diabetes management. When used consistently along with lifestyle improvements, it may have a positive impact on blood glucose control. This medication is used for improving blood glucose control.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride, as extended-release, 2000 mg. This medicine should be taken with food once daily, preferably with the evening meal. For this medicine 5/1000 mg extended-release tablets, take 1 tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin therapy - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medicine is an antidiabetic agent primarily composed of metformin hydrochloride and linagliptin. Care should be taken as rare cases of severe lactic acidosis may occur with the use of this medication. Lactic acidosis is a dangerous condition resulting from an excessive accumulation of lactic acid in the body, which can be life-threatening without immediate treatment. This medication should not be administered to individuals with certain medical conditions, such as allergies to the ingredients, type 1 diabetes, severe renal impairment, acute infections, severe liver dysfunction, or acute alcohol intoxication. Additionally, it should not be used in acute situations that may affect kidney function, such as dehydration, severe infections, or acute myocardial infarction. There is a risk of hypoglycemia while taking this medication, especially when taken with insulin or sulfonylureas, so blood glucose levels should be closely monitored. Symptoms of lactic acidosis may include abdominal pain, muscle cramps, and feelings of weakness; if these symptoms occur, consult a doctor immediately. Since renal function plays a crucial role, kidney function should be regularly monitored before and during treatment, and the medication may need to be discontinued if kidney function declines. This medication should be stopped for a certain period before and after surgery or radiographic procedures with iodine contrast, and resumed only after renal function has recovered post-surgery. Rare side effects such as acute pancreatitis or blistering dermatitis (similar to pemphigus) have been reported; if these symptoms occur, discontinue use and consult a healthcare professional immediately. Metformin can lower vitamin B12 levels with prolonged use, so blood tests may be needed to check vitamin B12 status and supplementation may be required. This medication should be swallowed whole without chewing or crushing. Its film coating may appear in stools, which is normal. Since this medication may interact with other drugs, it is essential to inform your doctor or pharmacist about any other medications being taken. It is advisable to avoid this medication during pregnancy or breastfeeding, and consult a healthcare provider if planning a pregnancy. Elderly patients may commonly experience reduced kidney function, so renal function should be checked frequently during use and the dosage adjusted if necessary. In cases of overdose, severe side effects such as lactic acidosis may occur, so strictly adhere to the recommended dosage; in cases of overdose, seek immediate medical attention. Store this medication out of reach of children, avoid moisture, and do not transfer it to other containers.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • nasopharyngitis
  • hypersensitivity reactions
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemia
  • dysgeusia
Show 126 more
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • pemphigoid-like eruption
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • anorexia
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's-type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot syndrome
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • chest discomfort
  • weakness
  • pain
  • epistaxis
  • oropharyngeal pain
  • speech disorder
  • allergic rhinitis
  • exertional dyspnea
  • wet cough
  • rhinorrhea
  • lung mass
  • arthralgia
  • osteoporosis
  • joint disease
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • androgenetic alopecia
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • periodontitis
  • influenza
  • gingivitis
  • altered mental state
  • nocturia
  • dermatitis
  • hypotension
  • flushing
  • hearing loss
  • erectile dysfunction
  • goiter

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent exposure to air and moisture. It is recommended to maintain storage temperatures between 1 and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Oval sustained release tablet in white to nearly white color imprinted with L2M on one side

Package unit

28 tablets/box [7 tablets/PTP x 4], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.